The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, or esophageal cancers. As of the data cutoff date of June 10, 32 patients had been treated. EO-3021 was observed to be generally welltolerated. No Grade 4 or 5 treatment-r ...